Metzger Michael A 4
4 · Syndax Pharmaceuticals Inc · Filed Mar 6, 2025
Insider Transaction Report
Form 4
Metzger Michael A
DirectorChief Executive Officer
Transactions
- Exercise/Conversion
Common Stock
2025-03-04$7.20/sh+7,814$56,261→ 307,935 total - Sale
Common Stock
2025-03-04$15.05/sh−7,814$117,564→ 300,121 total - Exercise/Conversion
Stock options (Right to buy)
2025-03-04+7,814→ 0 totalExercise: $7.20Exp: 2025-06-01→ Common Stock (7,814 underlying)
Footnotes (3)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person solely covering equity grants with expiration dates prior to September 10, 2025. Following the sales reported in this Form 4, the Reporting Person has a total of 1,321,245 options to purchase shares of common stock that are vested and immediately exercisable and a total of 805,428 options to purchase shares of common stock that have not yet vested.
- [F2]The sale prices ranged from $15.00 to $15.27
- [F3]This option is fully vested.